If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
==== Marina ==== Marina facilities, primarily targeted at recreational sailing and power boating, are provided in both the historic Wellington Dock and adjacent to the cruise terminal and cargo wharves.
==== International ==== DET is listed under Schedule I of the United Nations 1971 Convention on Psychotropic Substances, placing it under international control. This means that countries that are parties to the Convention are required to regulate DET production, distribution, and use, restricting it to scientific and very limited medical purposes. Possession and trade of DET without appropriate authorization is prohibited under international law.
=== Clinical and clinicopathologic research and scholarship === Jennette and his associates have performed and published clinical and clinicopathologic studies, and recommendations for the management, diagnosis, and classification of kidney diseases. He was a member of consensus groups that published recommendations for pathologic diagnosis of kidney transplant rejection, focal segmental glomerulosclerosis, IgA nephropathy, membranoproliferative glomerulonephritis, C1q nephropathy, membranous nephropathy, lupus nephritis, and ANCA glomerulonephritis. In 1994 and 2012, Jennette and his associate Falk led two international consensus conferences that standardized the names and pathologic features of different forms of vascular inflammation (vasculitis). Jennette and Falk established the Glomerular Disease Collaborative Network (GDCN) in 1985 to promote collaborative research on glomerular disease among UNC faculty in nephrology and nephropathology, along with community practice nephrologists who refer kidney biopsies to UNC for diagnosis. Clinical and clinicopathologic research projects have utilized GDCN resources, including the article published by Jennette and Falk in The New England Journal of Medicine in 1988, which reported the discovery that one major antigen target of ANCA is myeloperoxidase (MPO-ANCA) and clarified the diverse clinical and pathologic spectrum of ANCA disease, using data and samples obtained through the GDCN. In 1990, they documented that the other major antigen specificity of ANCA is proteinase 3 (PR3-ANCA).
Sources: en.wikipedia.org
Von Willebrand disease (VWD) is a type of blood-clotting disorder. It is the most common hereditary coagulopathy in humans, affecting 1% of the population. An acquired form of VWD can sometimes result from other medical conditions. Most people with VWD have no symptoms. Those that do usually have bleeding of varying intensity, including repeated bruising and nosebleeds. VWD arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a protein required for platelet adhesion through the binding to other proteins, particularly factor VIII. The disease is known to affect several breeds of dogs as well as humans. Four types of hereditary VWD have been described, including platelet-type VWD, with VWD type 1 being the most common. Types 1 and 2 are inherited through an autosomal dominant pattern, meaning at least one parent must also have the disease. Diagnosis is typically confirmed through blood tests. Managing VWD includes the use of desmopressin after minor trauma or before surgery, which allows the body to release more VWF. The disease is named after the Finnish physician Erik Adolf von Willebrand, who first described the condition in 1926.
In the 1961 season, he guest-starred in an episode of NBC's Western Bonanza titled "Broken Ballad". In the 1961–1962 season, he guest-starred on ABC's crime drama Target: The Corruptors! and that network's The Rifleman. In the 1962–1963 season, he guest-starred in NBC's modern Western series Empire starring Richard Egan. In 1964, Culp played Charlie Orwell, an alcoholic veterinarian, in an episode of The Virginian (NBC 1962–1971) titled "The Stallion". That same year, he appeared in yet another Western, Gunsmoke. In the series' episode "Hung High", he portrays an outlaw named Joe Costa, who attempts to frame Matt Dillon for lynching a prisoner who had killed the marshal's friend. In 1965, he was cast as Frank Melo in "The Tender Twigs" of James Franciscus's NBC education drama series, Mr. Novak. Culp then played perhaps his most memorable character, American secret agent Kelly Robinson, who operated undercover as a touring tennis professional, for three years on the hit NBC series I Spy (1965–1968), with co-star Bill Cosby. Culp wrote the scripts for seven episodes, one of which he also directed and an episode earned him an Emmy nomination for writing. For all three years of the series, he was also nominated for an acting Emmy (Outstanding Performance by an Actor in a Leading Role in a Dramatic Series category), but lost each time to Cosby.
== Further reading == Hồ NT, Hughes SG, Ta VT, Phan LT, Đỗ Q, Nguyễn TV, et al. (May 2024). "Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials". Nature Communications. 15 (1) 4081. Bibcode:2024NatCo..15.4081H. doi:10.1038/s41467-024-47905-1. PMC 11094049. PMID 38744844.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.